Jennifer S Rabin1, Hyun-Sik Yang2,3, Aaron P Schultz2,4, Bernard J Hanseeuw2, Trey Hedden4, Anand Viswanathan5, Jennifer R Gatchel1, Gad A Marshall2,3, Emily Kilpatrick2, Hannah Klein2, Vaishnavi Rao2, Rachel F Buckley2,3,6,7, Wai-Ying Wendy Yau2, Dylan R Kirn2, Dorene M Rentz2,3, Keith A Johnson2,3,4,8, Reisa A Sperling2,3,4, Jasmeer P Chhatwal2,3. 1. Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA. 2. Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA. 3. Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. 4. Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA. 5. J. Philip Kistler Stroke Research Center, Massachusetts General Hospital, Boston, MA. 6. Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia. 7. Melbourne School of Psychological Sciences, University of Melbourne, Parkville, Victoria, Australia. 8. Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Abstract
OBJECTIVE: Neuropathological studies have demonstrated that cerebrovascular disease and Alzheimer disease (AD) pathology frequently co-occur in older adults. The extent to which cerebrovascular disease influences the progression of AD pathology remains unclear. Leveraging newly available positron emission tomography (PET) imaging, we examined whether a well-validated measure of systemic vascular risk and β-amyloid (Aβ) burden have an interactive association with regional tau burden. METHODS: Vascular risk was quantified at baseline in 152 clinically normal older adults (mean age = 73.5 ± 6.1 years) with the office-based Framingham Heart Study cardiovascular disease risk algorithm (FHS-CVD). We acquired Aβ (11 C-Pittsburgh compound B) and tau (18 F-flortaucipir) PET imaging on the same participants. Aβ PET was performed at baseline; tau PET was acquired on average 2.98 ± 1.1 years later. Tau was measured in the entorhinal cortex (EC), an early site of tau deposition, and in the inferior temporal cortex (ITC), an early site of neocortical tau accumulation associated with AD. Linear regression models examined FHS-CVD and Aβ as interactive predictors of tau deposition, adjusting for age, sex, APOE ε4 status, and the time interval between baseline and the tau PET scan. RESULTS: We observed a significant interaction between FHS-CVD and Aβ burden on subsequently measured ITC tau (p < 0.001), whereby combined higher FHS-CVD and elevated Aβ burden was associated with increased tau. The interaction was not significant for EC tau (p = 0.16). INTERPRETATION: Elevated vascular risk may influence tau burden when coupled with high Aβ burden. These results suggest a potential link between vascular risk and tau pathology in preclinical AD. Ann Neurol 2019; 1-8 ANN NEUROL 2019;85:272-279.
OBJECTIVE: Neuropathological studies have demonstrated that cerebrovascular disease and Alzheimer disease (AD) pathology frequently co-occur in older adults. The extent to which cerebrovascular disease influences the progression of AD pathology remains unclear. Leveraging newly available positron emission tomography (PET) imaging, we examined whether a well-validated measure of systemic vascular risk and β-amyloid (Aβ) burden have an interactive association with regional tau burden. METHODS: Vascular risk was quantified at baseline in 152 clinically normal older adults (mean age = 73.5 ± 6.1 years) with the office-based Framingham Heart Study cardiovascular disease risk algorithm (FHS-CVD). We acquired Aβ (11 C-Pittsburgh compound B) and tau (18 F-flortaucipir) PET imaging on the same participants. Aβ PET was performed at baseline; tau PET was acquired on average 2.98 ± 1.1 years later. Tau was measured in the entorhinal cortex (EC), an early site of tau deposition, and in the inferior temporal cortex (ITC), an early site of neocortical tau accumulation associated with AD. Linear regression models examined FHS-CVD and Aβ as interactive predictors of tau deposition, adjusting for age, sex, APOE ε4 status, and the time interval between baseline and the tau PET scan. RESULTS: We observed a significant interaction between FHS-CVD and Aβ burden on subsequently measured ITC tau (p < 0.001), whereby combined higher FHS-CVD and elevated Aβ burden was associated with increased tau. The interaction was not significant for EC tau (p = 0.16). INTERPRETATION: Elevated vascular risk may influence tau burden when coupled with high Aβ burden. These results suggest a potential link between vascular risk and tau pathology in preclinical AD. Ann Neurol 2019; 1-8 ANN NEUROL 2019;85:272-279.
Authors: Jennifer S Rabin; Aaron P Schultz; Trey Hedden; Anand Viswanathan; Gad A Marshall; Emily Kilpatrick; Hannah Klein; Rachel F Buckley; Hyun-Sik Yang; Michael Properzi; Vaishnavi Rao; Dylan R Kirn; Kathryn V Papp; Dorene M Rentz; Keith A Johnson; Reisa A Sperling; Jasmeer P Chhatwal Journal: JAMA Neurol Date: 2018-09-01 Impact factor: 18.302
Authors: Samuel N Lockhart; Michael Schöll; Suzanne L Baker; Nagehan Ayakta; Kaitlin N Swinnerton; Rachel K Bell; Taylor J Mellinger; Vyoma D Shah; James P O'Neil; Mustafa Janabi; William J Jagust Journal: Neuroimage Date: 2017-02-21 Impact factor: 6.556
Authors: Keith A Johnson; Aaron Schultz; Rebecca A Betensky; J Alex Becker; Jorge Sepulcre; Dorene Rentz; Elizabeth Mormino; Jasmeer Chhatwal; Rebecca Amariglio; Kate Papp; Gad Marshall; Mark Albers; Samantha Mauro; Lesley Pepin; Jonathan Alverio; Kelly Judge; Marlie Philiossaint; Timothy Shoup; Daniel Yokell; Bradford Dickerson; Teresa Gomez-Isla; Bradley Hyman; Neil Vasdev; Reisa Sperling Journal: Ann Neurol Date: 2015-12-15 Impact factor: 10.422
Authors: Julie A Schneider; Patricia A Boyle; Zoe Arvanitakis; Julia L Bienias; David A Bennett Journal: Ann Neurol Date: 2007-07 Impact factor: 10.422
Authors: Elizabeth C Mormino; Rebecca A Betensky; Trey Hedden; Aaron P Schultz; Rebecca E Amariglio; Dorene M Rentz; Keith A Johnson; Reisa A Sperling Journal: JAMA Neurol Date: 2014-11 Impact factor: 18.302
Authors: Renée F A G de Bruijn; Michiel J Bos; Marileen L P Portegies; Albert Hofman; Oscar H Franco; Peter J Koudstaal; M Arfan Ikram Journal: BMC Med Date: 2015-07-21 Impact factor: 8.775
Authors: Saffire H Krance; Hugo Cogo-Moreira; Jennifer S Rabin; Sandra E Black; Walter Swardfager Journal: J Neurosci Date: 2019-07-26 Impact factor: 6.167
Authors: Vladimir Hachinski; Karl Einhäupl; Detlev Ganten; Suvarna Alladi; Carol Brayne; Blossom C M Stephan; Melanie D Sweeney; Berislav Zlokovic; Yasser Iturria-Medina; Costantino Iadecola; Nozomi Nishimura; Chris B Schaffer; Shawn N Whitehead; Sandra E Black; Leif Østergaard; Joanna Wardlaw; Steven Greenberg; Leif Friberg; Bo Norrving; Brian Rowe; Yves Joanette; Werner Hacke; Lewis Kuller; Martin Dichgans; Matthias Endres; Zaven S Khachaturian Journal: Alzheimers Dement Date: 2019-07 Impact factor: 21.566
Authors: Daniel Albrecht; A Lisette Isenberg; Joy Stradford; Teresa Monreal; Abhay Sagare; Maricarmen Pachicano; Melanie Sweeney; Arthur Toga; Berislav Zlokovic; Helena Chui; Elizabeth Joe; Lon Schneider; Peter Conti; Kay Jann; Judy Pa Journal: J Neurosci Date: 2020-10-12 Impact factor: 6.167
Authors: Jodie B Nichols; Michael Malek-Ahmadi; Pierre N Tariot; Geidy E Serrano; Lucia I Sue; Thomas G Beach Journal: J Neuropathol Exp Neurol Date: 2021-02-22 Impact factor: 3.685
Authors: Chia-Chen Liu; Yu Yamazaki; Michael G Heckman; Yuka A Martens; Lin Jia; Akari Yamazaki; Nancy N Diehl; Jing Zhao; Na Zhao; Michael DeTure; Mary D Davis; Lindsey M Felton; Wenhui Qiao; Yonghe Li; Hongmei Li; Yuan Fu; Na Wang; Melissa Wren; Tomonori Aikawa; Marie-Louise Holm; Hiroshi Oue; Cynthia Linares; Mariet Allen; Minerva M Carrasquillo; Melissa E Murray; Ronald C Petersen; Nilüfer Ertekin-Taner; Dennis W Dickson; Takahisa Kanekiyo; Guojun Bu Journal: Alzheimers Dement Date: 2020-08-22 Impact factor: 16.655